LSX 2024 - James Graham, Recce Pharma
A lot of ink has been spilled about the anti-microbial resistance space and why it’s so hard to create a profitable company in it. But that hasn’t stopped some start-ups from making the effort, and even seeing some success.
At LSX 2024 in Boston last month, editor-in-chief Jonah Comstock spoke with James Graham, CEO and founder of Recce Pharma, an Australian start-up creating a new antibiotic for sepsis, focusing in the short term on diabetic foot ulcers.
Graham discusses how a narrow focus that lines up with an unmet medical need is allowing his company to make headway in a traditionally difficult space. He describes some of their ongoing studies and their support from the US Department of Defense.
He also talks about the advantages of starting a biotech company in Australia and shares some of what he heard at a previous conference, the World AMR Congress, about trends in superbugs more broadly.
Check out the video below for a spotlight on an interesting start-up making waves in a challenging therapeutic area.
